Reply to Rheumatologists’ perspective on coronavirus disease 19: is heparin the dark horse for COVID-19?

Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets

(2020) Durga Prasanna Misra et al.   CLINICAL RHEUMATOLOGY

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

(2020) Ning Tang et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19

(2020) Muthiah Vaduganathan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Haemostatic and inflammatory alterations in familial hypercholesterolaemia, and the impact of angiotensin II infusion

(2015) Mikael Ekholm et al.   JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM

The Angiotensin-Converting Enzyme 2/Angiotensin-(1–7)/Mas receptor axis: A potential target for treating thrombotic diseases

(2012) Rodrigo Fraga-Silva et al.   THROMBOSIS AND HAEMOSTASIS

Inhibition of SARS Pseudovirus Cell Entry by Lactoferrin Binding to Heparan Sulfate Proteoglycans

(2011) Jianshe Lang et al.   PLoS One